Company Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer.
The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures.
The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors.
NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
| Country | United States |
| Founded | 2015 |
| IPO Date | May 9, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Michael Richman |
Contact Details
Address: 9000 Virginia Manor Road, Suite 200 Beltsville, Maryland 20705 United States | |
| Phone | 240 399 4900 |
| Website | nextcure.com |
Stock Details
| Ticker Symbol | NXTC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001661059 |
| CUSIP Number | 65343E207 |
| ISIN Number | US65343E2072 |
| Employer ID | 47-5231247 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael S. Richman MSBA | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Timothy Mayer Ph.D. | Chief Operating Officer |
| Dr. Solomon Langermann Ph.D. | Chief Scientific Officer |
| Dr. Lieping Chen M.D., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Steven P. Cobourn CPA | Chief Financial Officer |
| Kevin G. Shaw | Senior Vice President and General Counsel |
| Sourav Kundu Ph.D. | Senior Vice President of Development and Manufacturing |
| Dr. Sebastien Maloveste Ph.D. | Senior Vice President of Business Development |
| Dr. Udayan Guha M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Aug 7, 2025 | 8-K | Current Report |
| Jul 29, 2025 | EFFECT | Notice of Effectiveness |
| Jul 29, 2025 | 424B2 | Prospectus |
| Jul 18, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 14, 2025 | 8-K | Current Report |
| Jul 10, 2025 | 8-K | Current Report |
| Jun 23, 2025 | 8-K | Current Report |
| Jun 16, 2025 | 8-K | Current Report |
| May 19, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |